Search Orphan Drug Designations and Approvals
-
| Generic Name: | a novel CRISPR/Cas13X RNA base-editing therapy drug |
|---|---|
| Date Designated: | 02/29/2024 |
| Orphan Designation: | Treatment of OTOF Q829X mutation-induced hearing loss |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Cholgene Therapeutics, Inc. 651N. Broad Street, Suite 206 Middletown, Delaware 19709 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







